Testing a new pill to prevent lung cancer return after surgery

Plain-English translation of NCT04853342 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Read our Non-small Cell Lung Carcinoma research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called Furmonertinib to see if it can help prevent lung cancer from returning after surgery. The study focuses on people whose tumors have specific genetic changes (EGFR mutations) that make them sensitive to this type of treatment. Half of the participants will receive the medication daily, and the other half will receive a placebo (a pill with no active ingredient) to compare how well the treatment works.

Even after surgery removes all visible cancer, some patients with early-stage lung cancer experience a recurrence. Researchers believe this medication could help reduce that risk in patients with specific genetic mutations, potentially improving long-term outcomes and survival.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with early-stage lung cancer (stages II or IIIA) with specific EGFR genetic mutations
you have had complete surgical removal of your tumor with clear margins and are fully recovered from surgery
you are in good overall health, able to care for yourself, and perform light activities
you are willing to take a daily oral medication and commit to study visits and monitoring

You likely don't qualify if…

you have had radiation therapy before or after your surgery for this cancer
you have received chemotherapy before surgery or are planning to receive EGFR inhibitor medications
you have a history of other cancers (except non-melanoma skin cancer treated successfully more than 5 years ago)
you are taking medications that interfere with how your body processes this drug, or you have severe heart, liver, or kidney problems
you are pregnant, breastfeeding, or unable to swallow pills or absorb medications normally

What participation looks like

If you join this study, you will be randomly assigned to take either the new medication or a placebo by mouth once daily. You will need to visit the clinic regularly for blood tests, heart monitoring, and check-ins to see how you are doing and watch for any side effects. The study will continue for an extended period as researchers track whether the medication helps prevent your cancer from returning.

AI-generated summary from trial data · Aug 29, 2026 · Not medical advice

Testing a new pill to prevent lung cancer return after surgery

What is this trial?

Do you qualify?

What participation looks like

Trial locations